Clinical Trial Update: A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals [Phase 3]

View source ↗

Summary

Phase III trial of MP-101 for short bowel syndrome has been withdrawn due to inadequate response to anti-diarrheals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• MP-101

Snippet

Sponsor: Marathon Pharmaceuticals, LLC | Conditions: Short Bowel Syndrome, Short Gut Syndrome | Phase 3 | Status: WITHDRAWN